A double-blind, randomized, placebo-controlled, single dose escalation study to investigate the safety, tolerability and pharmacokinetics of GSK1349572 in healthy subjects.

Trial Profile

A double-blind, randomized, placebo-controlled, single dose escalation study to investigate the safety, tolerability and pharmacokinetics of GSK1349572 in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2010

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Mar 2010 Last checked against ClinicalTrials.gov record.
    • 01 Jan 2010 Results published in the Antimicrobial Agents and Chemotherapy.
    • 21 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top